The week in health tech, explained in plain English.Get the free newsletter →
November 22, 2026

Takeaways from the most recent news in the technology and policies shaping healthcare.

Government

Stem Cell Advocates Eye FDA Opening Under RFK Jr.

Stem cell advocates are betting that their treatments could be the next peptides: products that move from regulatory limbo to tacit acceptance at the FDA, according to STAT News. The template is recent. Peptides, long sold in gray markets and prized in wellness circles, gained a measure of legitimacy after the Make America Healthy Again movement embraced them under HHS Secretary Robert F. Kennedy Jr.

Now backers of stem cell therapies hope to follow the same path. The pitch leans on political alignment with MAHA rather than on new clinical evidence, and that is the core tension. Many stem cell offerings sold directly to patients remain unproven, and the FDA has historically cracked down on clinics marketing them for conditions ranging from arthritis to neurological disease.

For the broader industry, the question is whether regulatory posture, not data, becomes the deciding factor. A friendlier FDA could expand patient access and investment, but it could also loosen guardrails on therapies that lack rigorous evidence of safety and efficacy.

Sources

More in Government

Government

CMS Proposes Sweeping Medicare Advantage Changes for 2028

CMS's proposed 2028 rule would overhaul Medicare Advantage market entry, provider networks, and star ratings while adding a mandatory state-based payment model.

Why it matters: Medicare Advantage covers more than 35 million people, and these changes would reshape plan revenue, competition, and provider contracting.

Government

Michigan Pharmacy Owner Gets 82 Months in $5.6M Fraud Case

Michigan pharmacy owner Ali Naserdean was sentenced to 82 months for a $5.6 million payer fraud scheme and illegally distributing oxycodone, the DOJ said.

Why it matters: Pharmacy billing fraud and opioid diversion remain prime federal enforcement targets, raising the stakes for payer and health-system claims integrity.